López FLH, Alfonso RE, Llerena RLD, González VA, Señor DR, Rodríguez NLM, Zabala GA, Roldos CEE, Barreda PAM

Language: Spanish
References: 0
Page: 1-9
PDF size: 284.75 Kb.

ABSTRACT

Introduction: Cardiovascular diseases represent the leading causes of death in the world and in Cuba. Percutaneous coronary intervention with drug-eluting stents has improved the treatment and evolution of these patients. Objective: To describe the clinical and angiographic characteristics of patients treated with ihtDEStiny stents and to identify major cardiac adverse events during clinical follow-up. Method: An observational, analytical and prospective study was carried out at the Instituto de Cardiología y Cirugía Cardiovascular of Havana, from June 2019 to December 2020, including the first 50 consecutive patients treated in Cuba with abluminal-coated sirolimus-eluting stent. Results: The mean age was 61.5 years old, with a predominance of males (88%). The predominant cardiovascular risk factor was high blood pressure (37 patients [74%]), followed by diabetes mellitus (13 [26%]). Seventy-nine stenoses were treated with a predominance of type B2 (48.1%) and an average of 1.58 stents per patient were implanted, in 60% of cases directly. The left anterior descending was the most affected coronary artery, the immediate success of the procedure was 98.7% and few major cardiac adverse events were detected after a clinical follow-up at 6 and 12 months. Conclusions: The treated patients show profiles of age, gender and risk factors similar to those of the rest of patients with coronary artery disease. The sirolimus drug-eluting stents used in this study are safe and guarantee a period free from major cardiac adverse events.